PTGS2 and cancer: These include loss of WNT1-inducible-signaling pathway protein 3 (WISP3) [11]; overexpression of epidermal growth factor receptor (EGFR) [12], HER2 [13], TIG1/Axl [14], E-cadherin [15], Ras homolog gene family member C (RhoC), and GTPase [16]; overexpression of inflammatory mediators Janus kinase (JAK)/signal transducers and activators of transcription (STAT) [17,18], nuclear factor kappa B (NF-κB) [19,20,21], and Cyclooxygenase-2 (COX-2) [20,22] as well as angiogenic factors [23,24] and translation initiation factor eIF4GI [25]; and enrichment of the cancer stem cell (CSC) population [26].